Literature DB >> 2851448

Tumor necrosis factor alpha stimulates leukotriene production in vivo.

M Huber1, B Beutler, D Keppler.   

Abstract

Tumor necrosis factor alpha, or cachectin (TNF), is a polypeptide mediator with proinflammatory and antitumor actions. It is produced in large amounts by lipopolysaccharide (LPS)-activated macrophages. TNF as well as LPS stimulated the arachidonate cascade leading to the synthesis of leukotrienes (LT) in vivo. Production of endogenous cysteinyl LT was measured in anesthetized rat using the biliary excretion of N-acetyl-LTE4 as an indicator. Infusion of TNF over a 1-h period greatly increased the rate of cysteinyl LT production during the subsequent 3 h. Pretreatment with anti-TNF antibody F(ab')2 fragments prevented enhanced LT generation as well as tachypnea (a sign of the in vivo action of TNF). LT production elicited by TNF was similar to that evoked by infusion of LPS. Our results indicate that lipoxygenase products are involved in the network of pathophysiological events induced by TNF. The proinflammatory and shock-inducing LT may mediate many of the adverse effects of TNF in vivo as well as its antitumor action.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2851448     DOI: 10.1002/eji.1830181233

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  14 in total

Review 1.  Mechanisms of organ dysfunction in critical illness: report from a Round Table Conference held in Brussels.

Authors:  M P Fink; T W Evans
Journal:  Intensive Care Med       Date:  2002-02-08       Impact factor: 17.440

2.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs.

Authors:  F D Pagani; L S Baker; C Hsi; M Knox; M P Fink; M S Visner
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

3.  Protective effects of a leukotriene inhibitor and a leukotriene antagonist on endotoxin-induced mortality in carrageenan-pretreated mice.

Authors:  M Ogata; T Matsumoto; M Kamochi; S I Yoshida; Y Mizuguchi; A Shigematsu
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

4.  Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.

Authors:  M A Saad; R M Abdelsalam; S A Kenawy; A S Attia
Journal:  Neurochem Res       Date:  2014-11-18       Impact factor: 3.996

5.  Spectral analysis of heart rate variability in the sepsis syndrome.

Authors:  C S Garrard; D A Kontoyannis; M Piepoli
Journal:  Clin Auton Res       Date:  1993-02       Impact factor: 4.435

Review 6.  Targeting TNF-alpha: a novel therapeutic approach for asthma.

Authors:  Christopher Brightling; Mike Berry; Yassine Amrani
Journal:  J Allergy Clin Immunol       Date:  2007-11-26       Impact factor: 10.793

7.  Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat.

Authors:  C Denzlinger; M Grimberg; A Kapp; C Haberl; W Wilmanns
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

8.  Platelet-activating factor and endotoxin induce tumour necrosis factor gene expression in rat intestine and liver.

Authors:  L Huang; X Tan; S E Crawford; W Hsueh
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

9.  The immunocytochemical localization of tumour necrosis factor and leukotriene in the rat liver after treatment with lipopolysaccharide.

Authors:  T Nagano; T Kita; N Tanaka
Journal:  Int J Exp Pathol       Date:  1992-10       Impact factor: 1.925

10.  TNF induces c-fos via a novel pathway requiring conversion of arachidonic acid to a lipoxygenase metabolite.

Authors:  E M Haliday; C S Ramesha; G Ringold
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.